A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

Item
http://www.wikidata.org/entity/Q58271878
New developments and future opportunities in biomarkers for amyotrophic lateral sclerosisALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.Use of biomarkers in ALS drug development and clinical trialsMetabolomics in amyotrophic lateral sclerosis: how far can it take us?Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Further development of biomarkers in amyotrophic lateral sclerosis.Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis.Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.Biomarkers in Neurodegenerative Diseases.Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis.Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement.Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms.Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression.
P2860

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

Item
http://www.wikidata.org/entity/Q58271878
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2014
@uk
name
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial
@nl
type
label
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial
@nl
prefLabel
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
A post hoc analysis of subgrou ...... OWER) of dexpramipexole in ALS
@en
P2093
P2860
P304
P31
P356
10.3109/21678421.2014.943672
P433
P478
P50
P577
P698
P921